Health and Fitness Health and Fitness
Thu, October 28, 2010
[ Thu, Oct 28th 2010 ] - Market Wire
Pro-Pharmaceuticals Ships First Commercial Order for DAVANAT®
[ Thu, Oct 28th 2010 ] - Market Wire
Curis Reports Third Quarter 2010 Financial Results
[ Thu, Oct 28th 2010 ] - Market Wire
BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update
[ Thu, Oct 28th 2010 ] - Market Wire
AngioDynamics Announces Election of Kevin J. Gould to Board of Directors
Wed, October 27, 2010
[ Wed, Oct 27th 2010 ] - Market Wire
Sanofi-aventis video Q&A: CFO J©r'me Contamine Comments on Results for Q3 2010
[ Wed, Oct 27th 2010 ] - Market Wire
Exact Sciencesa? Abstract Published in AACR Abstr .. dation Study Data Will Be Announced at 1:00 PM ED
[ Wed, Oct 27th 2010 ] - Market Wire
NeuroMetrix, Inc. Announces Date for 2010 Third Quarter Financial Results Conference Call
[ Wed, Oct 27th 2010 ] - Market Wire
Crown Oil and Gas Announces Appointment of Director
[ Wed, Oct 27th 2010 ] - Market Wire
Finkelstein Thompson LLP Announces Investigation of Clarient, Inc.
[ Wed, Oct 27th 2010 ] - Market Wire
NUVO RESEARCH ANNOUNCES 2010 THIRD QUARTER FINANCIAL RESULTS
[ Wed, Oct 27th 2010 ] - Market Wire
NPS Pharmaceuticals to Report Third Quarter 2010 Financial Results
[ Wed, Oct 27th 2010 ] - Market Wire
Somaxon Pharmaceuticals to Report Third Quarter 2 .. nd Conduct Conference Call on Tuesday, November 9
[ Wed, Oct 27th 2010 ] - Market Wire
Human Genome Sciences Announces Third Quarter 2010 Financial Results and Key Developments
[ Wed, Oct 27th 2010 ] - Market Wire
Dyax Corp. Announces Third Quarter 2010 Financial Results
[ Wed, Oct 27th 2010 ] - Market Wire
China Kanghui Holdings Announces Participation in Upcoming Investor Conferences
[ Wed, Oct 27th 2010 ] - Market Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2010 Financial Results
[ Wed, Oct 27th 2010 ] - Market Wire
Chemed Corporation to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Wed, Oct 27th 2010 ] - Market Wire
Northstar Healthcare Announces Senior Management Changes
[ Wed, Oct 27th 2010 ] - Market Wire
IMRIS TO HOLD THIRD QUARTER 2010 RESULTS CONFERENCE CALL
[ Wed, Oct 27th 2010 ] - Market Wire
Nova superfcie teraputica da KCI melhora a integr .. ara a preveno e a administrao de lceras de presso
[ Wed, Oct 27th 2010 ] - Market Wire
New therapeutisch verband van KCI verbetert kwalteit van de huid en voorkomt decubitus
[ Wed, Oct 27th 2010 ] - Market Wire
Gilead Sciences, Linear Technology, Biogen Idec, Elan and Novartis
[ Wed, Oct 27th 2010 ] - Market Wire
Alexion to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Wed, Oct 27th 2010 ] - Market Wire
La nueva superficie terap©utica de KCI mejora la .. ara la prevencin y el manejo de lceras por presin
[ Wed, Oct 27th 2010 ] - Market Wire
Nuova superficie terapeutica sviluppata da KCI ri .. la prevenzione e la gestione delle piaghe da dec
[ Wed, Oct 27th 2010 ] - Market Wire
Neue therapeutische Oberflche von KCI verbessert .. tegritt fr Prvention und Management von Dekubitus
[ Wed, Oct 27th 2010 ] - Market Wire
GTx Announces Pricing of Public Offering of Common Stock
[ Wed, Oct 27th 2010 ] - Market Wire
ZIOPHARM Oncology to Present at Oppenheimer 21st Annual Healthcare Conference
[ Wed, Oct 27th 2010 ] - Market Wire
Bond Labsa? Resurrectiona" Conducts In-Store Promotions for Cub Foods®
[ Wed, Oct 27th 2010 ] - Market Wire
ARIAD to Present at the Oppenheimer & Co. 21st Annual Healthcare Conference

ARIAD to Present at the Oppenheimer & Co. 21st Annual Healthcare Conference


Published on 2010-10-27 04:41:37 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it is scheduled to present at the Oppenheimer & Co. 21st Annual Healthcare Conference being held at the Waldorf=Astoria Hotel in New York City. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, November 2, 2010 at 10:15 a.m. (ET).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://investor.ariad.com ]. A replay of the presentation will be available on the ARIAD website approximately 24 hours after the presentation and will be archived for three weeks.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].

Contributing Sources